Stealth Bio Posts Encouraging Preclinical Data In Parkinson's Animal Studies

  • Stealth BioTherapeutics Corp MITO has presented new data from a study evaluating SBT-272 in a murine model of Parkinson's disease (PD). 
  • SBT-272 is a mitochondria-targeted product candidate, which is known to cross the blood-brain barrier. 
  • The data were presented at the International Parkinson and Movement Disorder Society Virtual Congress 2021.
  • Systemic daily administration of SBT-272 at two doses significantly protected against the loss of dopaminergic neurons and the aggregation of pathological alpha-synuclein. 
  • In addition, the higher dose of SBT-272 significantly reduced two different markers of neuroinflammation. Overall, the data demonstrate that SBT-272 has a neuroprotective effect in this model of PD.
  • In this study, systemic SBT-272 treatment protected brain mitochondria against damage caused by an ischemic stroke. 
  • The Company plans to advance SBT-272 in dose-ranging Phase 1 studies early next year in addition to initiating chronic toxicology studies to support Phase 2 initiation.
  • Price Action: MITO stock is down 1.37% at $1.44 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsParkinson’s DiseasePreclinical Phase
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!